Pyxis Oncology, Inc. (PYXS)

US — Healthcare Sector
Peers: LPTX  ZURA  XFOR  ELEV  BMEA  HOWL  DRMA 

Automate Your Wheel Strategy on PYXS

With Tiblio's Option Bot, you can configure your own wheel strategy including PYXS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PYXS
  • Rev/Share 0.1005
  • Book/Share 1.4154
  • PB 2.7059
  • Debt/Equity 0.2221
  • CurrentRatio 5.6543
  • ROIC -0.9752

 

  • MktCap 237529457.0
  • FreeCF/Share -1.1911
  • PFCF -3.2206
  • PE -2.463
  • Debt/Assets 0.158
  • DivYield 0
  • ROE -0.828

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation PYXS Guggenheim -- Buy -- $5 Sept. 4, 2025

News

Should You Buy Pyxis Oncology, Inc. (PYXS) After Golden Cross?
PYXS
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive

Pyxis Oncology, Inc. (PYXS) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PYXS's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Read More
image for news Should You Buy Pyxis Oncology, Inc. (PYXS) After Golden Cross?
Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
ALLO, PYXS, RLAY
Published: September 08, 2025 by: Zacks Investment Research
Sentiment: Positive

Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.

Read More
image for news Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
PYXS
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders

Read More
image for news Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
PYXS, RLAY, VSTM
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive

If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.

Read More
image for news Top Cancer Stocks to Buy to Boost Your Portfolio's Health

About Pyxis Oncology, Inc. (PYXS)

  • IPO Date 2021-10-08
  • Website https://www.pyxisoncology.com
  • Industry Biotechnology
  • CEO Lara S. Sullivan MBA
  • Employees 44
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.